NCT06149663

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Expanded Access Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP)

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Longboard Pharmaceuticals · Industry
• Sex: All
• Age: 2 Years – 65 Years
• Healthy volunteers: —

Summary

This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.

Conditions

• Dravet Syndrome
• Lennox Gastaut Syndrome
• Developmental and Epileptic Encephalopathies

Interventions

Type	Name	Description
DRUG	LP352	LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.

Timeline

• First posted: 2023-11-29
• Last updated: 2025-01-22

Locations

22 sites across 2 countries: United States, Australia